New pill for Hard-to-Treat cancers shows early promise in small study
NCT ID NCT06625515
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new oral drug, ATX-559, in 17 people with advanced solid tumors that had stopped responding to standard treatments. The main goal was to find a safe dose and check for side effects. The study was terminated early, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
Stephenson Cancer Center at OU Medicine
Oklahoma City, Oklahoma, 73104, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
University of Colorado Cancer Center - Anschutz Medical Campus,
Aurora, Colorado, 80045, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can your own immune cells beat advanced cancer?
- Can diet and vitamin c supercharge rectal cancer treatment?
- Digital nurse companion: could an app ease the burden of chronic illness?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- What raises endometrial cancer risk in black women? a study digs in
- Tumor DNA mapping may unlock personalized cancer therapies